Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Uber Technologies Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Uber Technologies Inc trades at $75.04 (market cap $151.73B). The key difference: Uber Technologies Inc is far larger — about 3.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Uber Technologies Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | UBER | |
|---|---|---|
Market Cap | $39.89B | $151.73B |
Sector | Health | Industrials |
52-Week High | $491.22 | $100.10 |
52-Week Low | $278.09 | $68.61 |
Enterprise Value | $38.15B | $158.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Uber Technologies (UBER) trades at $74.54, showing modest daily gains of 0.26%. The stock maintains strong bullish technical momentum with positive moving average signals and trades near pivot point resistance at $75. Fundamentally, Uber demonstrates robust revenue growth from $31.9B in 2022 to $52.0B in 2025, with net income turning positive since 2023 and reaching $10.05B in 2025. Recent developments include strategic moves into autonomous vehicles with robotaxi pilots in Madrid and Munich.
Uber presents a compelling growth story with expanding profitability and dominant market position. The 81.7% analyst buy rating and $109.25 consensus price target suggest 46% upside potential. Key risks include execution challenges in autonomous vehicle expansion, competitive pressures in key markets like India, and potential margin compression as revenue growth moderates. The negative projected net cash flow for 2026 warrants monitoring of capital allocation strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
